sam537

I have completely lost track of what I have read and my thoughts. I really should journal. That being said as somebody else mentioned this is very pleasing to the eye. The UI with no ads and no buy buttons is so refreshing. I see that some of the covers are from specific editions. Any way to change those? Where are they coming from? I will give it a try and add a few books and see. Good job!

I came to say this. Free episode to listen to. If you are interested in this it is Nx more cost-effective to listen to Liemandt than to read the adjective laden article.

Popular and incompletely understood. That analogy is unhelpful to understand processes. It's attempting to explain a incompletely understood phenomenon with another. As someone else said below, the problem of the genome being the 'compressed representation' is reductive since genomes do not exist in isolation in an organism. Genomes were environmentally selected for millenia and many unicellular organisms share genomic material with other organisms or the environment. I think the framework is useful but it does not scale.

You should check out a currently approved drug that is very similar called amivantamab (Rybrevant). Also targets EGFR and MET (MET can sometimes be a resistance mechanism to EGFR blockade).

The problem here is the potential toxicity of this combination. In lung cancer for example, the combination of anti-EGFR therapy + pembrolizumab led to deadly pneumonitis (lung inflammation). We want to cure more patients, but we don't want to kill them before their cancer.

Maybe I can help. Progression is usually defined by radiological endpoints (RECIST 1.1 criteria) meaning that at timepoint x the tumor stayed the same size, got smaller, or grew less than 20%. Radiological measurement is very subjective so most of these trials centralize measurement of 'target lesions' (some patients have many tumors but not all are measured in clinical trials). It is worth nothing that inside PFS not only progression is an event but also death. So if you progressed and/or died, you count as an event.

The overall response rate is a combination of complete response (tumor not measurable radiologically) and partial response (>20% reduction in size). That is a common trial endpoint.

As someone else said the Breakthrough designation is common and does not necessarily lead to efficacious drug approvals.

I am close to some of these institutions and it pains me to hear the trouble you had just getting an answer a yes or no answer or getting your paperwork checked for eligibility. In large institutions there is not only an institutional culture but a Department-specific culture (as crazy as that sounds!). I am lucky to be part of a Department that has a immediate attention and transfer attitude from leadership and it permeates down to the faculty and next-day appointment slots are kept open and things accommodated.

I wish you the best, and it makes me want to work even harder to hear about the challenges we still face.

Some comments about dietary science are true. It is extremely impossible to isolate the effect of a single substance (ethically).

This person greatly benefited from stopping caffeine intake which is great. It is part of the journey to understand ourselves and what makes us work/improve/feel better.

If you have a anxiety-o-meter that looks like this: [-----------------------------------]

and your baseline is here: [-------------------------X---------] - you just need a little push to go into anxiety/can't sleep mode which can come from caffeine.

But if your baseline is around here: [--x--------------------------------] -maybe some coffee in the morning, right after lunch will greatly increase your clarity/make you able to fulfill your duties. People who drink caffeine for pleasure (I love the taste of coffee and sometimes I get beans so good that I just want to drink several cups) will notice the negative effect in their sleep/anxiety levels. We must go back to Paracelsus 'dosis sola facit venenum'. The dose makes the poison.

The text was ok, I do not know anything about spermatogenesis but a fair bit about the JAK/STAT pathway. The abstract was pure LLM, however. It has been retracted.

Not only that. The JAK "pathway" is complete gibberish. The third figure is a pool of random spheres in "differentiation" steps. The whole Frontiers publishing group is widely seen in academia as worthless, however, since most promotion committees just count the number of publications no matter where they may be, they continue to publish anything and make bank.

As an animal with similar fastidiousness, I agree. I am happy to have found this. Reminded me of After Dark by Murakami.

You should also try immunotherapy (pembrolizumab) with chemo if your CPS is >1% before experimental early phase trials.

Mildly interesting.

The lowest of the low? Based on consonant pronunciation? How can you extract a value judgment from how someone speaks?